[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression-moderate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression-moderate":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,67,92,119,143,166,188,210,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100572639","fmri-neurofeedback-with-matter-neuroscience-app-100572639",false,"NCT06735885","fMRI Neurofeedback With Matter Neuroscience App","Stanford-Matter Neuroscience High-Resolution fMRI Advanced Neurofeedback Feasibility Trial (fMRI Neurofeedback) Medical","Inclusion Criteria:\n\n1. Male or Female, between the ages of 18 and 80 at the time of screening.\n2. Primary diagnosis of nonpsychotic major depressive disorder (MDD) without a history of psychotic features.\n3. Score on the MADRS scale between 15-25\n4. Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires \u002F follow instructions during fMRI. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.\n5. Must possess an iPhone with the latest iOS version compatible with the app or must be willing to use a loaner iPhone from the study if available.\n6. Has had at least one lifetime antidepressant treatment failure (ATHF)\n7. The dose of the primary antidepressant medication (if applicable) must be stable for 4 weeks prior to baseline, and participants must agree to continue at this dose throughout the study period.\n8. In good general health, as evidenced by medical history and determined by study physician\n9. For women of reproductive potential: agree to the use of highly effective contraception during study participation.\n10. Adequate visual acuity (with or without corrective lenses) to view study materials while in the MRI.\n11. Agreement to adhere to Lifestyle Considerations throughout study duration.\n\nExclusion Criteria:\n\n1. Contraindication to MRI (ferromagnetic metal in their body)\n2. Severe claustrophobia\n3. Women that are pregnant or breastfeeding or with a positive urine pregnancy test at participation, or who are planning to become pregnant during the study period.\n4. Primary psychiatric condition other than MDD requiring treatment except stable comorbid anxiety disorder\n5. History of or current psychotic disorder, schizophrenia, psychosis, bipolar disorder, or severe borderline personality disorder.\n6. Diagnosis of intellectual disability, autism spectrum disorder, or other neurodevelopmental disorder.\n7. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n8. Urine screening test positive for recent use of recreational drugs except for marijuana..\n9. Considered at significant risk for suicide during the course of the study.\n10. Recent (within 4 weeks of any clinical effect) or concurrent use of rapid acting antidepressant agent (i.e., a course of ECT or TMS). Excluding ketamine.\n11. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma as determined by the PD.\n12. Untreated or insufficiently treated endocrine or metabolic disorder.\n13. Any other condition deemed by the PD to interfere with the study or increase risk to the participant\n14. Alexithymia as determined by the Toronto Alexithymia Scale\n15. Treatment with an investigational drug or other intervention within the study period.\n16. Not currently in a major depressive episode as defined by the MINI.\n17. More than 5 lifetime adequate antidepressant medication failures (ATHF).","ALL","18 Years","80 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","Study will utilize an app, Matter Neuroscience, designed to help users with depression understand positive emotions and the neurotransmitters that create them. We hope to learn the safety and efficacy of neurofeedback for treating depression and lay the groundwork for a pivotal clinical trial.",[27,28,29],"Depression Mild","Depression","Depression Moderate","RECRUITING","2026-05-20",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":34},"2025-08-12",{"date":38,"type":21},"2028-06-15",{"name":40,"class":41},"Stanford University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100517175","paramedical-tele-education-on-moderate-depressive-episodes-100517175","NCT06014125","Paramedical Tele-education on Moderate Depressive Episodes","Tele-education in Patients With a Moderate Depressive Episode in Primary Care","TE-DSP","Inclusion Criteria:\n\n* Presenting a depressive episode of moderate intensity according to the Diagnostic and Statistical Manual (DSM)-V\n* With a prescription for an antidepressant started less than 2 months before inclusion in the trial.\n* Whose state of health is compatible with follow-up by their GP (possibility of occasional advice from a psychiatrist).\n* Have Internet access at home (computer) and are able to use the digital platform.\n\nExclusion Criteria:\n\n* Patients who are unable to complete self-questionnaires (language barrier, etc.)\n* Who have already undergone a psycho-education or therapeutic patient education programme regarding depression.\n* Whose state of health requires follow-up by a psychiatrist",{"count":52,"type":21},220,[24],"Considering that one out of five people may experience depression during the course of their life, and that compliance to anti-depression medication is often not optimal.\n\nPsycho-educational interventions are recommended in international clinical practice guidelines for the management of depression. They are the first step in the treatment protocol.\n\nPsychoeducation in the treatment of depressive episodes has been shown to be an effective intervention because it reduces depressive symptoms, the risk of relapse or recurrence and improves adherence to treatment.\n\nIn France, there are only one approved psycho-education programme, but it concerns a population of patients under psychiatric care.\n\nNo psycho-education programme has yet been carried out or evaluated in France on depressed patients followed up in primary care by their General Practitioner.\n\nRecent changes in our healthcare practices, which have required adaptation to the pandemic context, have led to the development of the use of telemedicine.\n\nThis study aims to evaluate a new and 100% remote educational program adapted to patients ongoing moderate depression and focused on medication adherence, economic gain and patients and professional satisfaction.",[28,29],[57],"psychoeducation","2026-05-07",{"date":60,"type":34},"2026-05-12",{"date":62,"type":34},"2024-01-25",{"date":64,"type":21},"2028-12",{"name":66,"class":41},"University Hospital, Toulouse",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":42},"100523123","treating-major-depression-with-yoga-mono-therapy-100523123","NCT06091527","Treating Major Depression With Yoga Mono-therapy","Treating Major Depression With Yoga Mono-therapy: 12-Week Randomized Controlled Trial","Inclusion criteria:\n\n* 18 years of age or older\n* Able to give voluntary, informed consent\n* English-speaking\n* Diagnosis of clinical depression\n\nExclusion criteria:\n\n* Current use of antidepressant medication\n* Current engagement in psychotherapy\n* Current pregnancy\n* Significant medical issues interfering with yoga practice",{"count":75,"type":21},180,[24],"The goal of this single-center, single-blind, randomized, controlled, parallel group, interventional trial is to evaluate antidepressant efficacy of yoga monotherapy of 12-weeks duration in 180 adults meeting diagnostic criteria for mild-to-moderate major depression at the Zuckerberg San Francisco General Hospital. Researchers will compare the yoga interventions to an education control intervention on holistic healthcare.",[27,29],[80,81,82],"yoga","ayurveda","depression","2025-11-04",{"date":85,"type":34},"2025-11-06",{"date":87,"type":34},"2024-10-25",{"date":89,"type":21},"2026-06",{"name":91,"class":41},"University of California, San Francisco",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":17,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":42},"100537143","telehealth-behavioral-activation-for-teens-100537143","NCT06273995","Telehealth Behavioral Activation for Teens","Inclusion Criteria:\n\n1. Participants must be enrolled in the Texas Youth Depression Suicide Research Network (TX-YDSRN) Registry Study;\n2. Be between the ages of 12- 18 or currently enrolled in high school;\n3. Have a caregiver that is willing to participate in the program;\n4. Be able to commit to weekly sessions for eight weeks;\n5. Be currently experiencing depressive symptoms;\n6. Be able to participate in telehealth services within the state of Texas;\n7. Be willing to provide consent\u002Fassent (parents\u002Flegally authorized representative (LAR)\u002Fguardian or young adult participant, aged 18 or older, must be willing to provide consent; youth, aged 12-17, must be willing to provide assent);\n8. Be able to read, write and speak English or Spanish sufficiently to understand the study procedures and provide written informed consent to participate in the study;\n9. Be willing to dedicate appropriate time to complete scheduled study assessment and measures and attend intervention sessions (both parent\u002FLAR\u002Fguardian and youth)\n10. Be able to provide a reliable means of contact.\n\nExclusion Criteria:\n\n1. Have an acute medical or psychological condition(s) that that would, in the judgment of the study medical clinician, make participation difficult or unsafe;\n2. Have an acute medical or psychological condition(s) that would result in an inability to accurately complete study requirements (e.g., neurological conditions or significant neurodevelopmental concerns);\n3. Have active psychotic or manic symptoms resulting in altered mental status and inability to provide assent or requiring immediate attention and\u002For higher level of intervention;\n4. Have a parent\u002FLAR\u002Fguardian who is deemed cognitively unable to provide consent (if youth participant, aged 12-17).","12 Years",{"count":100,"type":21},250,[24],"Behavioral activation is one such empirically supported intervention. Derived from cognitive-behavioral therapy, a well-established treatment for depression, behavioral activation uses psychoeducation and skill-building to increase an individual's engagement in valued and enjoyable activities (e.g., socializing with family and friends, exercising, participating in a hobby) in order to improve depressive symptoms. Research has shown that behavioral activation is an effective intervention for depressed youth. Additionally, it has been shown as a promising intervention that can be conducted in a brief, virtual format and can be effectively implemented by both trained clinicians and trained, non-licensed interventionists. This project will provide Behavioral Activation for youth (12-17) experiencing depression or suicidal ideation who are currently enrolled in the Youth Depression Suicide Network study in Texas.",[28,104,105,27,29,106],"Suicide and Self-harm","Depression in Adolescence","Depression Severe",[108,82,109],"behavioral activation","adolescents","2025-07-18",{"date":112,"type":34},"2025-07-20",{"date":114,"type":34},"2024-03-01",{"date":116,"type":21},"2029-12-01",{"name":118,"class":41},"Baylor College of Medicine",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100505957","effects-and-cost-effectiveness-of-e-meistring---a-guided-internet-delivered-psychological-treatment-100505957","NCT05868135","Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment","Guided Internet-delivered Treatment for Moderate Depression, Social Anxiety Disorder and Panic Disorder - An Open Naturalistic Multicentre Cost-effectiveness Trial","Inclusion Criteria:\n\nHaving moderate depression, panic disorder and social anxiety disorder as a primary disorder. Access to computer and internet.\n\nExclusion Criteria:\n\nHaving severe depression, suicidal impulses and thoughts, bipolar disorders, psychosis, substance abuse, unstable medication last month, severe reading or writing disabilities.",{"count":127,"type":21},800,"OBSERVATIONAL","The goal of this observational multicentre study is to address the effectiveness and cost-effectiveness of providing a therapist guided internet based cognitive behavioural therapy (ICBT) for common mental disorders in a routine healthcare setting.\n\nMain research questions is 1) What is the effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics in routine care? 2) What is the cost-effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics? 3) Who benefits from guided internet-delivered treatment? 4) What are the predictors of drop-out from guided internet based treatment? 5) To what extent does user experiences of guided internet based treatment influence adherence and effectiveness? Participants will receive up to nine guided ICBT sessions (modules) and answer questionnaires covering symptoms severity, health related quality of life, work and social ability, user satisfaction and medication. All questionnaires are part of the standard patient follow up routines in the four treatment locations participating in the study. Analytical approach is to compare locations\u002Fclinics and subgroups of patients.",[29,131,132],"Anxiety, Social","Panic Disorder","2025-06-04",{"date":135,"type":34},"2025-06-05",{"date":137,"type":34},"2021-09-09",{"date":139,"type":21},"2027-12-31",{"name":141,"class":41},"St. Olavs Hospital",4,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":150,"sex":16,"minAge":151,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":42},"100578331","kintsugi-voice-device-pivotal-study-100578331","NCT06809907","Kintsugi Voice Device Pivotal Study","Kintsugi Voice Device SCID-5 Pivotal Study","Inclusion Criteria:\n\nAge \\>22 at the time of informed consent Self-reported disruption to activities of daily living (e.g. missed scheduled healthcare appointments, unable to concentrate on tasks like reading, working, or completing daily activities, or difficult completing activities such as exercise, diet, or recreation) Access to a laptop, smartphone, tablet, or other device with a functioning microphone and access to the Internet Stated willingness to be video and audio recorded as part of the study Stated willingness to comply with all study procedures and availability for the duration of the study Functional English capacity in the home environment Availability for the duration of the study Resides in the United States at the time of consent and during completion of study\n\n\\-\n\nExclusion Criteria:\n\n* Participants with at least one of the following conditions will be excluded:\n\nAny impairment that impacts their ability to speak and\u002For use a computer to complete online surveys and\u002For a virtual clinician assessment (E.g., visual impairment, motor impairment, and\u002For hearing impairment) Any lifetime history of neurological disease that impacts their ability to speak and\u002For use a computer to complete online surveys and\u002For a virtual clinician assessment (E.g., Central Nervous System disorders, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and\u002For Parkinson's Disease) Any lifetime history of Stroke, cognitive defect (E.g., dementia or Alzheimer's disease), and\u002For Traumatic Brain Injury Presence of voice disorders that impacts their ability to speak (E.g., acute or chronic laryngitis, vocal cord paresis or paralysis, or spasmodic dysphonia) Past or active heavy smokers (an average of \\>20 cigarettes per day) Subjects who have previously participated in any Kintsugi-sponsored study",true,"22 Years",{"count":153,"type":21},1000,"A prospective, single arm, non-randomized, pivotal clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made by a clinician using the Structured Clinical Interview for DSM-5 (SCID-5-RV) for up to 1000 English speaking adult patients ages 22 and older living in the United States. Recruitment will occur for 1 year and participation will be for up to 2 weeks",[28,29,106,27],"2025-04-28",{"date":158,"type":34},"2025-04-30",{"date":160,"type":34},"2025-03-27",{"date":162,"type":21},"2025-11",{"name":164,"class":165},"Kintsugi Mindful Wellness, Inc.","INDUSTRY",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":42},"100557419","icbt-for-seniors-with-depression-in-primary-care-100557419","NCT06537869","iCBT for Seniors With Depression in Primary Care","The New Internet Generation: iCBT Treatment for Seniors With Mild-moderate Depression - a Pragmatic Randomised Controlled Trial in the Primary Care Context","Inclusion Criteria:\n\n* All patients \\>65, attending PCCs engaged in the trial, with mood as well as somatic complaints will be asked about depressive symptoms during the last 2 weeks by NICE guidelines for depression.\n* All patients diagnosed with minor\u002Fmajor depression and not belonging to exclusion criteria and willing to take part in the trial will be diagnosed via the Mini International Neuropsychiatric Interview (M.I.N.I.) by a psychologist\u002Fspecially trained nurse and have a General Practitioner (GP) somatic consultation\n\nExclusion Criteria:\n\nPatients diagnosed with:\n\n* severe depression\n* prior suicide attempt or currently at medium to high risk of suicide (MADRS-S question 9\\>3 points or MINI suicide \\>9)\n* bipolar disorder\n* psychosis\n* addiction\n* cognitive impairment\n* not speaking or understanding Swedish.","65 Years",{"count":175,"type":21},390,[24],"This clinical trial aims to evaluate the potential benefits of internet cognitive behavioural therapy (iCBT) for elderly patients with mild\u002Fmoderate depression and compare its effectiveness with the current treatment as usual (TAU) at primary care centres (PCCs).\n\nThe specific aims are to study if:\n\niCBT is as effective as TAU in reducing depressive symptoms iCBT is as effective as TAU in increasing quality of life iCBT is as effective as TAU in increasing the function in patients \\>65 years and older with mild\u002Fmoderate depression attending primary care, with the perspective of 36 months.\n\nParticipants will:\n\nWork with the iCBT program (10-12 weeks) or become TAU at their PCCs. Followed-up at 3, 6, 12, 24 and 36 months of their symptoms, quality of life and function.",[27,29],"2025-03-31",{"date":181,"type":34},"2025-04-01",{"date":183,"type":34},"2024-09-01",{"date":185,"type":21},"2029-06",{"name":187,"class":41},"Göteborg University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":173,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":42},"100557174","the-cerebral-and-cognitive-changes-after-intermittent-theta-burst-stimulation-itbs-treatment-for-depression-100557174","NCT06534684","The Cerebral and Cognitive Changes After Intermittent Theta Burst Stimulation (iTBS) Treatment for Depression","The Cerebral and Cognitive Changes After Intermittent Theta Burst Stimulation (iTBS) Treatment for Depression A Randomised Double-blind Sham-controlled Trial","Inclusion criteria:\n\n* Patients must meet the diagnostic criteria of at least a moderate depression\n* The duration of the current depressive episode must have lasted more than 2 weeks but less than 2 years\n* Drug therapy must have been stable for the last three weeks prior to the first treatment day with iTBS\n* Patients must volunteer to provide informed consent, be able to follow the treatment schedule and have a satisfactory safety screening for iTBS and MRI\n\nExclusion criteria:\n\n* The current depressive episode is in the mild range\n* The current episode fulfills the criteria for a major depressive episode requiring inpatient treatment and\u002For electroconvulsive therapy,\n* The current depressive episode is clearly triggered by grief or a recent major stressful life event\n* Bipolar disorder\n* Borderline personality disorder\n* Psychotic symptoms\n* Alcohol or substance abuse\u002Faddiction in the last 6 months\n* Current eating disorders\n* Obsessive- compulsive disorders\n* Post-traumatic stress disorder\n* A life-time medical history of seizure\n* Neurological or neurosurgical pathologies\n* Cardiac or systemic disease\n* Metallic prosthetic material or foreign objects (pacemakers, prosthetic eye equipment, etc.)\n* Autism\n* Pregnancy\n* Currently using of antipsychotic medication or benzodiazepines - or any medication that interferes with motor threshold excitability",{"count":196,"type":21},50,[24],"The present project aims to assess the neurocognitive impact of a two-week once-a-day regimen of intermittent theta burst stimulation (iTBS) compared to sham iTBS, when targeting the left dorsolateral prefrontal cortex (LDLPFC) in clinically depressed outpatients. The study investigates the relationships between changes in cerebral measures and cognitive performance on an N-back task in relation to the antidepressive effect following iTBS.",[200,29],"Depression, Unipolar","2024-08-01",{"date":203,"type":34},"2024-08-02",{"date":205,"type":34},"2024-02-12",{"date":207,"type":21},"2029-02-12",{"name":209,"class":41},"University Hospital of North Norway",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":42},"100551195","a-pilot-study-comparing-the-efficacy-of-traditional-buddhist-mindfulness-training-versus-secular-mindfulness-based-cognitive-therapy-for-patients-having-residual-depressive-symptoms-100551195","NCT06456931","A Pilot Study Comparing the Efficacy of Traditional Buddhist Mindfulness Training Versus Secular Mindfulness-based Cognitive Therapy for Patients Having Residual Depressive Symptoms","Comparing the Efficacy of Traditional Buddhist Mindfulness Training Versus Secular Mindfulness-based Cognitive Therapy for Residual Depressive Symptoms in Patients With Depressive Disorders: a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 or above\n* Buddhist faith (Only Buddhists are selected as one of the interventions involves Buddhist teachings, and any recruited participant has a probability of being enrolled in the Buddhist mindfulness intervention)\n* A history of one or more episodes of moderate or severe depression\n* Currently having BDI-II score \\> 13, i.e., mild to moderate depressive symptoms\n\nExclusion Criteria:\n\n* Currently having a severe depressive episode, according to the Composite International Diagnostic Interview (CIDI) Sinhalese version\n* Currently having moderate to severe suicidal ideation (according to CIDI)\n* Recent changes in antidepressant medication\n* Unable to understand and communicate in Sinhalese",{"count":218,"type":21},60,[24],"This interventional study is conducted with the goal of comparing the efficacy of traditional Buddhist mindfulness training versus secular mindfulness based cognitive therapy among patients with depressive disorders. We are also interested in studying how these interventions compare in terms of preventing further relapses of depression. Additionally, this study aims to identify factors that influence the efficacy of this intervention, such as self-report mindfulness, self-compassion, and religiosity.",[29,27],[223,82,224],"mindfulness","religiosity","2024-06-07",{"date":227,"type":34},"2024-06-13",{"date":229,"type":34},"2024-04-01",{"date":231,"type":21},"2025-10-31",{"name":233,"class":41},"Anuradha Baminiwatta",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":173,"enrollmentInfo":242,"targetDuration":4,"studyType":22,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":256},"100499818","integrated-depression-care-100499818","NCT05788198","Integrated Depression Care","Integrated Depression Care Project","IDECA","Inclusion Criteria:\n\n* persons between 18-65\n* presenting to the general practitioner's office\n* with depressive symtomatology\n\nExclusion Criteria:\n\n* Severe depression warranting direct referral to specialized services\n\nInclusion criteria are kept broad on purpose as it's one of the research questions to define for which patients the intervention (namely the case management) is appropriate.",{"count":243,"type":21},150,[24],"The Integrated DEpression CAre (IDECA) Programme is a multi-faceted intervention strategy aiming to improve guideline adherence and shared care practices for depression management in both providers and patients, as measured through a set of process and clinical outcome indicators (primary outcome measure).",[27,29,106],"2024-06-05",{"date":249,"type":34},"2024-06-06",{"date":251,"type":34},"2023-04-25",{"date":253,"type":21},"2024-09-30",{"name":255,"class":41},"University Ghent",2]